{"id":146331,"date":"2025-03-18T16:32:40","date_gmt":"2025-03-18T11:02:40","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=146331"},"modified":"2025-03-18T16:32:43","modified_gmt":"2025-03-18T11:02:43","slug":"pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/","title":{"rendered":"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure &amp; kidney disease"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-4200634509\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>This pharma stock engaged in manufacturing and marketing pharmaceutical products, active pharmaceutical ingredients (APIs), diagnostics, and over-the-counter (OTC) healthcare products, skyrocketed 13 percent after launching Empamore, a new and affordable treatment for diabetes, heart failure, and chronic kidney disease.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1859429754\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Stock Price Movement:<\/strong><\/h2><p>With a market capitalization of Rs. 2,654.84 crores, the share of Morepen Laboratories Limited has reached an intraday high of Rs. 48.45 per equity share, rising nearly around 13.20 percent from its previous day\u2019s close price of Rs. 42.80. Since then, the stock has retreated and is currently trading at Rs. 48.35 per equity share.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened:<\/strong><\/h2><p>Morepen Laboratories has launched Empamore, a new and affordable treatment for diabetes, heart failure, and chronic kidney disease. With India having over 101 million diabetes patients, Empamore aims to provide quality care at nearly 90 percent lower costs than existing brands.&nbsp;<\/p><p>The product includes Empagliflozin tablets (10mg\/25mg) and combination tablets with Metformin (500mg\/1000mg). Manufactured in Morepen\u2019s USFDA-approved facility, Empamore ensures high quality while being budget-friendly. This launch reflects Morepen\u2019s commitment to providing affordable healthcare, helping millions of Indians manage their health without financial strain.<\/p><div class=\"trade-content_5\" id=\"trade-4251365295\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Product Portfolio:<\/strong><\/h2><p>Morepen offers a variety of products, including key pharmaceutical ingredients like Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. The company is also known for its medical devices, especially in point-of-care diagnostics. Morepen has sold over 12 million glucometers and nearly 1.65 billion blood glucose strips, helping people monitor their health easily and effectively.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Margin Guidance:<\/strong><\/h2><p>The company\u2019s management expects its profit margins to improve by focusing more on higher-profit finished dosage products and medical devices. Their long-term goal is to achieve an EBITDA margin of 15 percent. This improvement is expected to happen gradually as new products are launched and market conditions become more stable.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Future Outlook:<\/strong><\/h2><p>The management is cautiously optimistic about the future, expecting a growth rate of 10-15 percent in the coming years, depending on market conditions and new product launches. The company plans to maintain a 70:30 ratio of exports to domestic sales, aiming to boost profits through higher-margin export markets. Their key focus will be on expanding the medical devices segment and improving their product range in both the pharmaceutical and OTC categories.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Recent quarter results:<\/strong><\/h2><p>Morepen Laboratories Limited&#8217;s revenue has increased from Rs. 445 crore in Q3 FY24 to Rs. 453 crore in Q3 FY25, which has grown by 1.80 percent. The net profit has decreased by 15.63 percent from Rs. 32 crore in Q3 FY24 to Rs. 27 crore in Q3 FY25.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by &#8211; Nikhil Naik<\/strong><\/p><\/blockquote><\/blockquote><div class=\"trade-after-content\" id=\"trade-353813337\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>This pharma stock engaged in manufacturing and marketing pharmaceutical products, active pharmaceutical ingredients (APIs), diagnostics, and over-the-counter (OTC) healthcare products, skyrocketed 13 percent after launching Empamore, a new and affordable treatment for diabetes, heart failure, and chronic kidney disease. Stock Price Movement: With a market capitalization of Rs. 2,654.84 crores, the share of Morepen Laboratories [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":82826,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[],"class_list":["post-146331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure &amp; kidney disease<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure &amp; kidney disease\" \/>\n<meta property=\"og:description\" content=\"This pharma stock engaged in manufacturing and marketing pharmaceutical products, active pharmaceutical ingredients (APIs), diagnostics, and over-the-counter (OTC) healthcare products, skyrocketed 13 percent after launching Empamore, a new and affordable treatment for diabetes, heart failure, and chronic kidney disease. Stock Price Movement: With a market capitalization of Rs. 2,654.84 crores, the share of Morepen Laboratories [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T11:02:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-18T11:02:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/\",\"name\":\"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure & kidney disease\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\",\"datePublished\":\"2025-03-18T11:02:40+00:00\",\"dateModified\":\"2025-03-18T11:02:43+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure &amp; kidney disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure & kidney disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure &amp; kidney disease","og_description":"This pharma stock engaged in manufacturing and marketing pharmaceutical products, active pharmaceutical ingredients (APIs), diagnostics, and over-the-counter (OTC) healthcare products, skyrocketed 13 percent after launching Empamore, a new and affordable treatment for diabetes, heart failure, and chronic kidney disease. Stock Price Movement: With a market capitalization of Rs. 2,654.84 crores, the share of Morepen Laboratories [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-03-18T11:02:40+00:00","article_modified_time":"2025-03-18T11:02:43+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/","name":"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure & kidney disease","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","datePublished":"2025-03-18T11:02:40+00:00","dateModified":"2025-03-18T11:02:43+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-13-after-launching-affordable-treatment-for-diabetes-heart-failure-kidney-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 13% after launching affordable treatment for diabetes, heart failure &amp; kidney disease"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/146331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=146331"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/146331\/revisions"}],"predecessor-version":[{"id":146336,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/146331\/revisions\/146336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/82826"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=146331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=146331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=146331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}